Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK

被引:44
作者
Shearer, A
Bagust, A
Sanderson, D
Heller, S
Roberts, S
机构
[1] Univ York, York Hlth Econ Consortium, York YO10 5NH, N Yorkshire, England
[2] Sheffield Teaching Hosp NHS Trust, Sheffield, S Yorkshire, England
[3] Northumbria HealthCare NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England
关键词
Type; 1; diabetes; patient education; glycaemic control; cost-effectiveness; disease modelling;
D O I
10.1111/j.1464-5491.2004.01183.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To determine the cost-effectiveness of a structured treatment and teaching programme (STTP) combining dietary freedom with insulin adjustment for Type 1 diabetes. Methods Incremental cost-effectiveness analysis based on effectiveness data from three RCTs in Germany, Austria, and Dose Adjustment for Normal Eating (DAFNE) in the UK, to model the long-term microvascular complications of Type 1 diabetes. Results The STTP approach yields effectiveness gains at a lower cost compared with current standard practice for treatment of Type 1 diabetes. STTPs are likely to save 0.05 life years, yield 0.12 EuroQol 5 dimensions (EQ-5D) and 0.09 visual analogue scale (VAS) incremental quality-adjusted life years, and save approximately pound2200 per Patient treated discounted over 10 years. Conclusions Introducing STTPs as standard treatment for people with Type 1 diabetes in the UK may help to achieve the primary goal of the National Service Framework (NSF) for Diabetes by enabling individuals to manage their own lifestyle and condition. In doing so it could save valuable resources for the NHS and yield important morbidity and mortality gains.
引用
收藏
页码:460 / 467
页数:8
相关论文
共 33 条
[1]  
*AFNE STUD GROUP, 2002, BMJ-BRIT MED J, V325, P746
[2]  
[Anonymous], 2001, EXP PAT NEW APPR CHR
[3]  
Bagust A, 2002, DIABETES, V51, pA270
[4]   STROKE IN THE DIABETIC PATIENT [J].
BELL, DSH .
DIABETES CARE, 1994, 17 (03) :213-219
[5]   Intensified insulin therapy and the risk of severe hypoglycaemia [J].
Bott, S ;
Bott, U ;
Berger, M ;
Muhlhauser, I .
DIABETOLOGIA, 1997, 40 (08) :926-932
[6]  
*BRIT DIAB ASS, 1996, DIAB UK
[7]  
*BRIT MED ASS ROYA, 2001, BRIT NAT FORM, V41
[8]  
*CIPFA, 2001, HLTH SERV FIN DAT CO
[9]  
Currie CJ, 1997, DIABETIC MED, V14, P686, DOI 10.1002/(SICI)1096-9136(199708)14:8<686::AID-DIA434>3.3.CO
[10]  
2-4